Cargando…

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection

Detalles Bibliográficos
Autores principales:	Shah, Hitesh H., Uppal, Nupur N., Fishbane, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380430/ https://www.ncbi.nlm.nih.gov/pubmed/32734947 http://dx.doi.org/10.1016/j.xkme.2020.05.001

Ejemplares similares

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
por: Cizman, Borut, et al.
Publicado: (2020)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019)

Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
por: Narita, Ichiei, et al.
Publicado: (2022)

In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
por: Ylenia, Ingrasciotta, et al.
Publicado: (2019)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
por: Ingrasciotta, Ylenia, et al.
Publicado: (2020)

The Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with Aceruloplasminemia
por: Nagata, Soichiro, et al.
Publicado: (2017)

Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis
por: Kobayashi, Shizuka, et al.
Publicado: (2022)

Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China
por: Sui, Zhun, et al.
Publicado: (2019)

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

The effects of chronic glucorticoid stimulation on erythropoiesis in Cushing syndrome
por: Strouboulis, John, et al.
Publicado: (2022)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
por: Kato, Hideki, et al.
Publicado: (2017)

Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers
por: Bennett, C L, et al.
Publicado: (2014)

Erythropoiesis stimulating agents and reno-protection: a meta-analysis
por: Elliott, Steve, et al.
Publicado: (2017)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Yasukawa, Minoru, et al.
Publicado: (2022)

Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
por: Lee, Yu-Ting, et al.
Publicado: (2022)

Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023)

Phylogeny and Ontogeny of Erythropoiesis
por: Nunomura, Wataru, et al.
Publicado: (2015)

Hypothalamic-pituitary-adrenal axis in mechanically ventilated critically ill patients: incidence of hyporesponsiveness to stimulation and relationship to cytokine levels
por: Dimopoulou, I, et al.
Publicado: (2006)

The effect of altitude on erythropoiesis-stimulating agent dose, hemoglobin level, and mortality in hemodialysis patients
por: Sibbel, Scott, et al.
Publicado: (2016)

A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
por: Das, Monojit, et al.
Publicado: (2022)

Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis
por: Honda, Hirokazu, et al.
Publicado: (2016)

Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
por: Vu, Khoa, et al.
Publicado: (2021)

Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality
por: Karaboyas, Angelo, et al.
Publicado: (2020)

Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients
por: Anker, Stefan D., et al.
Publicado: (2009)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013)

Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients
por: Suttorp, Marit M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gk4kr0osd1svfqj6oac9aht3rb